GLATIRAMER ACETATE (GA) RESULTS IN SIGNIFICANT REDUCTIONS IN ANNUALIZED RELAPSE RATE (ARR) AND PROTECTIVE EFFECT ON DISIBILTIY PROGRESSION- RESULTS FROM A NETWORK META-ANALYSIS
Author(s)
Ivanescu C1, Wu Y2, Kool-Houweling LM1, van Engen A1
1Quintiles Advisory Services, Hoofddorp, The Netherlands, 2Teva Branded Pharmaceuticals Products R&D Inc, Frazer, PA, USA
OBJECTIVES: Comparative effectiveness of disease modifying therapies (DMTs) is required to inform clinical care and health policy. We performed a network meta-analysis (NMA) to estimate the relative efficacy of DMTs versus placebo and of GA versus other DMTs. METHODS: Systematic searches (September 2015) were conducted in MEDLINE, Embase, and Cochrane Library to identify RCTs evaluating alemtuzumab, daclizumab, dimethyl-fumarate, fingolimod, GA, interferon beta-1a, interferon beta-1b, laquinimod, natalizumab, ocrelizumab, peginterferon beta-1a and teriflunomide. The outcomes (ARR and 3 or 6 months confirmed disability progression [CDP]) were analysed using Bayesian random effects models. RESULTS: The NMA for ARR and CDP included 34 and 32 RCTs, respectively. All DMTs showed significant reductions in ARR vs placebo (18%-72%). GA significantly reduced ARR vs placebo (median rate ratio: 0.65, 95% CrI:0.58-0.71) and compared to interferon
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PND9
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Neurological Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now